2023 World Conference on Lung Cancer (Posters)-P2.05. Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Pdf Summary

A study presented at the International Association for the Study of Lung Cancer – World Conference on Lung Cancer (IASLC WCLC) evaluated the pharmacokinetics (PK) of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC). The study included data from two phase 3 studies: EMPOWER-Lung 1 and EMPOWER-Lung 3. The PK analysis showed that cemiplimab PK were similar in patients receiving cemiplimab as monotherapy or in combination with chemotherapy, irrespective of histology or the expression of programmed cell death-ligand 1 (PD-L1). The study also found that immunogenicity against cemiplimab was low and did not affect cemiplimab PK.<br /><br />In EMPOWER-Lung 1, cemiplimab significantly improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy. The study demonstrated that cemiplimab monotherapy was generally well-tolerated. In EMPOWER-Lung 3 Part 1, cemiplimab in combination with chemotherapy and ipilimumab increased OS compared to chemotherapy alone in patients with advanced NSCLC and PD-L1 expression of 50% or higher. In EMPOWER-Lung 3 Part 2, cemiplimab in combination with chemotherapy significantly improved OS compared to chemotherapy alone in patients with advanced NSCLC, irrespective of PD-L1 expression. The safety profile of cemiplimab combination therapies in both parts of EMPOWER-Lung 3 was consistent with previously reported data.<br /><br />The PK analysis included assessment of cemiplimab concentrations in serum at steady state. The results showed that cemiplimab exposure was similar regardless of histology or PD-L1 expression. The presence of anti-drug antibodies against cemiplimab was low and did not affect cemiplimab concentrations in serum.<br /><br />Overall, the study concluded that cemiplimab PK were similar in patients with NSCLC regardless of treatment (monotherapy or combination therapies) and tumor characteristics. The findings support the use of cemiplimab as a treatment option for patients with advanced NSCLC.

Asset Subtitle

Petra Rietschel

Meta Tag

Speaker Petra Rietschel

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

cemiplimab

pharmacokinetics

non-small cell lung cancer

NSCLC

EMPOWER-Lung 1

EMPOWER-Lung 3

monotherapy

chemotherapy

PD-L1 expression

overall survival